US4564633A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods useful for producing analgesia
Assignee: Procter and Gamble Co
•
Filing: 1984-11-28
•
Granted: 1986-01-14
•
Expires: 2004-11-28
Abstract
Abstract A composition, useful for producing analgesia in humans or lower animals, comprising a safe and effective amount of: an N-[(substituted pheynl)methyl]-cis-monounsaturated alkenamide pharmaceutically-acceptable salts thereof, or mixtures thereof; and a pharmaceutically-acceptable carrier. Preferably, these alkenamides are N-vanillyl-cis-monounsaturated alkenamides. Methods of treatment, comprising administering a safe and effective amount of these alkenamides, pharmaceutically-acceptable salts thereof, or mixtures thereof, include methods of parenteral, oral, and topical administration.
Inventors
- 👤 Thomas R. LaHann
- 👤 Brian L. Buckwalter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
80 words
A method for producing analgesia in humans or lower animals, which comprises administering to said human or lower animal a safe and effective amount of monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR5## wherein X is O or S; R is straight or branched, cis-monounsaturated alkenyl having from 11 to 23 carbon atoms; R 1 is OH or OCH 3 ; and R 2 is a short-chain ester containing from 1 to 6 carbon atoms.
Claim 2
Independent Claim
80 words
A method for producing analgesia in humans or lower animals, which comprises administering to said human or lower animal a safe and effective amount of monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR5## wherein X is O or S; R is straight or branched, cis-monounsaturated alkenyl having from 11 to 23 carbon atoms; R 1 is OH or OCH 3 ; and R 2 is a short-chain ester containing from 1 to 6 carbon atoms.
Claim 3
Dependent Claim
25 words
A method, according to claim 1, wherein R of said monoalkenamide compound is straight or branched, cis-monounsaturated alkenyl having from 16 to 21 carbon atoms.
Claim 4
Dependent Claim
12 words
A method, according to claim 2, wherein said monoalkenamide is administered intramuscularly.
Claim 5
Dependent Claim
20 words
A method, according to claim 2, for producing analgesia in humans or lower animals, wherein said monoalkenamide is administered orally.
Claim 6
Dependent Claim
12 words
A method, according to claim 2, wherein said monoalkenamide is administered topically.
Claim 7
Dependent Claim
78 words
A composition for producing analgesia in humans or lower animals, comprising: (a) a safe and effective amount of a monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR6## wherein X is O or S, R is straight or branched cis-monounsaturated alkenyl having from 11 to 23 carbon atoms, R 1 is OH or OCH 3 and R 2 is a short-chain ester containing from 1 to 6 carbon atoms; and (b) a pharmaceutically-acceptable carrier.
Claim 8
Dependent Claim
78 words
A composition for producing analgesia in humans or lower animals, comprising: (a) a safe and effective amount of a monoalkenamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR6## wherein X is O or S, R is straight or branched cis-monounsaturated alkenyl having from 11 to 23 carbon atoms, R 1 is OH or OCH 3 and R 2 is a short-chain ester containing from 1 to 6 carbon atoms; and (b) a pharmaceutically-acceptable carrier.
Claim 9
Dependent Claim
21 words
A composition, according to claim 1, wherein R is straight or branched, cis-monounsaturated alkenyl having from 16 to 21 carbon atoms.
Claim 10
Dependent Claim
13 words
A composition, according to claim 1, wherein R 1 is OCH 3 .
Claim 11
Dependent Claim
27 words
A composition, according to claim 1, comprising a pharmaceutically-acceptable salt of said monoalkenamide compound, selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
Claim 12
Dependent Claim
11 words
A composition, according to claim 1, wherein said monoalkenamide is N-[(4-acetoxy-3-methoxyphenyl)methyl]-9Z-octadecenamide.
Claim 13
Dependent Claim
20 words
A composition, according to claim 8, for parenteral administration, comprising at least about 90%, by weight, of said pharmaceutically-acceptable carrier.
Claim 14
Dependent Claim
21 words
A composition, according to claim 8, for oral administration, comprising from about 25% to about 50%, by weight, of said monoalkenamide.
References Cited (Backward Citations)
FR1336388A
Cited
US3268582A
Cited
BE626897A
Cited
US3621043A
Cited
US4238508A
Cited
US4313958A
Cited
US4401663A
Cited
US4443473A
Cited
US4424205A
Cited
US4493848A
Cited
JPS6139413A
Cited
JPS6147752A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-01-13 | 1989-07-15 | 1990-01-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-01-13 | 1993-07-15 | 1994-01-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-01-13 | 1997-07-15 | 1998-01-14 | $7700.00 | Window Closed / Lapsed |